Yuko Aoki

3.8k citations

66 papers · 3.3k · 1 hit paper · h-index 29

Impact in

Biological Psychiatry top 2%
- Tryptophan and brain disorders
Oncology top 5%
- Lung Cancer Research Studies

Papers in

Molecular Biology 36
- Cancer therapeutics and mechanisms 6
- Protein Kinase Regulation and GTPase Signaling 4
- PI3K/AKT/mTOR signaling in cancer 4
- Melanoma and MAPK Pathways 4
Infectious Diseases 9
- Antifungal resistance and susceptibility 8

Co-authors: Nobuya Ishii (15 shared papers)Takuo Tsukuda (9 shared papers)Nobuo Shimma (19 shared papers)Hiroshi Sakamoto (5 shared papers)Mikio Arisawa (9 shared papers)Takaaki A. Fukami (4 shared papers)Toshiyuki Tsukaguchi (4 shared papers)Hirosato Ebiike (9 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (8 papers)Cancer Science (4 papers)Bioorganic & Medicinal Chemistry (3 papers)Journal of Biological Chemistry (3 papers)Molecular Cancer Therapeutics (2 papers)
Partner nations: Japan United States Switzerland

In The Last Decade

Yuko Aoki

65 papers receiving 3.1k citations

Yuko Aoki's Hit Papers

align trajectories log scale

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant 2011 · 552 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2011 Cancer Cell

Peers

Countries citing papers authored by Yuko Aoki

Since Specialization

Citations

This map shows the geographic impact of Yuko Aoki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Aoki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Aoki more than expected).

Fields of papers citing papers by Yuko Aoki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuko Aoki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Aoki. The network helps show where Yuko Aoki may publish in the future.

Co-authors

The 25 scholars most cited alongside Yuko Aoki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yuko Aoki Line = papers co-authored together Yuko Aoki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant Cancer Cell ·Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A. Fukami, Nobuhiro Oikawa, Takuo Tsukuda Hit paper breakdown →	2011	552
2	Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells Clinical Cancer Research ·Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai, Satoshi Takakura, Misato Saito, Yuko Aoki, Nobuya Ishii, Nozomu Yanaihara	2005	344
3	Host sphingolipid biosynthesis as a target for hepatitis C virus therapy Nature Chemical Biology ·Hiroshi Sakamoto, Koichi Okamoto, Masahiro Aoki, Hideyuki Kato, Asao Katsume, Atsunori Ohta, Takuo Tsukuda, Nobuo Shimma	2005	165
4	Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity Cancer Research ·Nobuya Ishii, Naoki Harada, Eric W. Joseph, Kazuhiro Ohara, Takaaki Miura, Hiroshi Sakamoto, Yutaka Matsuda, Yasushi Tomii	2013	141
5	Tetracycline-Regulatable System To Tightly Control Gene Expression in the Pathogenic Fungus Candida albicans Infection and Immunity ·Hironobu Nakayama, Toshiyuki Mio, Shigehisa Nagahashi, Michiko Kokado, Mikio Arisawa, Yuko Aoki	2000	135
6	Crystal Structures of Candida albicans N-Myristoyltransferase with Two Distinct Inhibitors Chemistry & Biology ·Satoshi Sogabe, Miyako Masubuchi, Kiyoaki Sakata, Takaaki A. Fukami, Kenji Morikami, Yasuhiko Shiratori, Hirosato Ebiike, Ken‐ichi Kawasaki	2002	112
7	Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase Bioorganic & Medicinal Chemistry ·Miyako Masubuchi, Hirosato Ebiike, Ken‐ichi Kawasaki, Satoshi Sogabe, Kenji Morikami, Yasuhiko Shiratori, Shinji Tsujii, Toshihiko Fujii	2003	111
8	Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N -myristoyltransferase. Part 1 Bioorganic & Medicinal Chemistry Letters ·Miyako Masubuchi, Ken‐ichi Kawasaki, Hirosato Ebiike, Yoshihiko Ikeda, Shinji Tsujii, Satoshi Sogabe, Toshihiko Fujii, Kiyoaki Sakata	2001	108
9	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor Molecular Cancer Therapeutics ·Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyoaki Sakata, Hitoshi Sase, Takehito Isobe, Kenji Morikami	2014	108
10	N,N,N′,N′-Tetraalkyl-2,2′-dihydroxy-1,1′-binaphthyl-3,3′-dicarboxamides: Novel Chiral Auxiliaries for Asymmetric Simmons–Smith Cyclopropanation of Allylic Alcohols and for Asymmetric Diethylzinc Addition to Aldehydes Bulletin of the Chemical Society of Japan ·Hiroshi Kitajima, Katsuji Ito, Yuko Aoki, Tsutomu Katsuki	1997	98
11	Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3 Bioorganic & Medicinal Chemistry Letters ·Ken‐ichi Kawasaki, Miyako Masubuchi, Kenji Morikami, Satoshi Sogabe, Tsunehisa Aoyama, Hirosato Ebiike, Satoshi Niizuma, Michiko Hayase	2003	92
12	The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations Clinical Cancer Research ·Hiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, Toshihiko Fujii, Kiyoaki Sakata, Yukako Tachibana, Jun Ohwada, Hirosato Ebiike	2011	91
13	Self-Enhancement of Hepatitis C Virus Replication by Promotion of Specific Sphingolipid Biosynthesis PLoS Pathogens ·Yuichi Hirata, Kazutaka Ikeda, Masayuki Sudoh, Yuko Tokunaga, Akemi Suzuki, Leiyun Weng, Masatoshi Ohta, Yoshimi Tobita	2012	72
14	Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2 Bioorganic & Medicinal Chemistry Letters ·Hirosato Ebiike, Miyako Masubuchi, Pingli Liu, Ken‐ichi Kawasaki, Kenji Morikami, Satoshi Sogabe, Michiko Hayase, Toshihiko Fujii	2002	69
15	Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799 Bioorganic & Medicinal Chemistry Letters ·Jun Ohwada, Hirosato Ebiike, Hatsuo Kawada, Masao Tsukazaki, Mitsuaki Nakamura, Takuya Miyazaki, Kenji Morikami, Kiyoshi Yoshinari	2011	64
16	Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity The Prostate ·Hiromitsu Kawata, Nobuyuki Ishikura, Miho Watanabe, Ayako Nishimoto, Toshiaki Tsunenari, Yuko Aoki	2010	56
17	Depletion of the Squalene Synthase ( ERG9 ) Gene Does Not Impair Growth of Candida glabrata in Mice Antimicrobial Agents and Chemotherapy ·Hironobu Nakayama, Miho Izuta, Noboru Nakayama, Mikio Arisawa, Yuko Aoki	2000	47
18	An orally available, small-molecule interferon inhibits viral replication Scientific Reports ·Hideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, Hitoshi Yoshino, Hiroshi Ohmori, Motooki Ashihara, Yuichi Hirata, Atsunori Ohta	2012	45
19	Asymmetric Simmons-Smith Cyclopropanation of E-Allylic Alcohols Using 1,1′-Bi-2-naphthol-3,3′-dicarboxamide as a Chiral Auxiliary Chemistry Letters ·Hiroshi Kitajima, Yuko Aoki, Katsuji Ito, Tsutomu Katsuki	1995	43
20	Azoxybacilin, a novel antifungal agent produced by Bacillus cereus NR2991. Production, isolation and structure elucidation. The Journal of Antibiotics ·Morio Fujiu, SAYOKO SAWAIRI, Hisao Shimada, HIROKI TAKAYA, Yuko Aoki, Tôru Okuda, Kazuteru Yokose	1994	42

About Yuko Aoki

Yuko Aoki is a scholar working on Molecular Biology, Infectious Diseases, Organic Chemistry, Hepatology and Oncology, having authored 66 papers that have together received 3.3k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (8 papers), Cancer therapeutics and mechanisms (6 papers), Hepatitis C virus research (5 papers), Synthesis and biological activity (5 papers), Protein Kinase Regulation and GTPase Signaling (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Melanoma and MAPK Pathways (4 papers) and Computational Drug Discovery Methods (3 papers). The work is most often cited by research in Biological Psychiatry (204 citations), Oncology (646 citations), Organic Chemistry (717 citations), Molecular Biology (1.5k citations) and Behavioral Neuroscience (69 citations). Yuko Aoki has collaborated with scholars based in Japan, United States and Switzerland. Frequent co-authors include Nobuya Ishii, Takuo Tsukuda, Nobuo Shimma, Hiroshi Sakamoto, Mikio Arisawa, Takaaki A. Fukami, Toshiyuki Tsukaguchi, Hirosato Ebiike, Kiyoaki Sakata and Takamitsu Kobayashi. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Cancer Science, Bioorganic & Medicinal Chemistry, Journal of Biological Chemistry and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Yuko Aoki

Impact in

Papers in i

In The Last Decade

Yuko Aoki

Yuko Aoki's Hit Papers

Peers

Countries citing papers authored by Yuko Aoki

Fields of papers citing papers by Yuko Aoki

All Works

About Yuko Aoki

Explore authors with similar magnitude of impact

Papers in